CovidResearchTrials by Shray Alag

CovidResearchTrials Covid 19 Research using Clinical Trials (Home Page)

Analysis of cytokine response, innate and adaptive immune response, complement activation, and serum neurofilaments as a marker of neurological damage.Wiki

Developed by Shray Alag
Clinical Trial MeSH HPO Drug Gene SNP Protein Mutation


Correlated Drug Terms (1)

Name (Synonyms) Correlation
drug3367 no intervention Wiki 0.38

Correlated MeSH Terms (2)

Name (Synonyms) Correlation
D045169 Severe Acute Respiratory Syndrome NIH 0.05
D018352 Coronavirus Infections NIH 0.04

Correlated HPO Terms (0)

Name (Synonyms) Correlation

There is one clinical trial.

Clinical Trials

1 Characterizing the Immune Response and Neuronal Damage in SARS-CoV-2 Infected Individuals

The Investigators plan to study the innate and adaptive immune response, the inflammatory response, and associated complications such as complement activation and neurological damage in SARS-Cov-2 infected individuals. Patients with mild, moderate and severe COVID-19 disease will be enrolled.

NCT04510012 SARS-CoV Infection Covid-19 Other: Analysis of cytokine response, innate and adaptive immune response, complement activation, and serum neurofilaments as a marker of neurological damage.
MeSH:Coronavirus Infections Severe Acute Respiratory Syndrome

Primary Outcomes

Description: Measurement of cytokine concentration (pg/ml) in serum (IL-6, IL-8, IL-1b,TNF-alpha)

Measure: Cytokine response to SARS-Cov-2

Time: At enrollment

Description: Measurement of cytokine concentration (pg/ml) in serum (IL-6, IL-8, IL-1b,TNF-alpha)

Measure: Cytokine response to SARS-Cov-2

Time: 28 days (+/-7) after enrollment

Description: Measurement of HLA-DR expression on CD14+ cells (flowcytometry)

Measure: Innate immune response to SARS-Cov-2

Time: At enrollment

Description: Measurement of HLA-DR expression on CD14+ cells (flowcytometry)

Measure: Innate immune response to SARS-Cov-2

Time: 3 days after enrollment

Description: Measurement of HLA-DR expression on CD14+ cells (flowcytometry)

Measure: Innate immune response to SARS-Cov-2

Time: 5 days after enrollment

Description: Measurement of neutralizing SARS-Cov-2 antibody concentrations (plaque reduction assay)

Measure: Humoral immune response

Time: At enrollment

Description: Measurement of frequencies of SARS-Cov-2 specific T-cells (ELISPOT assay)

Measure: Cell mediated immune response

Time: At enrollment

Description: Measurement of frequencies of SARS-Cov-2 specific T-cells (ELISPOT assay)

Measure: Cell mediated immune response

Time: 28 days (+/-7) after enrollment

Description: Measurement of neurofilament light chains in serum (on ELLA platform; Protein Simple, Bio-techne)

Measure: Neurological damage

Time: At enrollment

Description: Measurement of neurofilament light chains in serum (on ELLA platform; Protein Simple, Bio-techne)

Measure: Neurological damage

Time: 28 days (+/-7) after enrollment

Secondary Outcomes

Description: Measurement of factor B, factor H, factor I, C3a, C4a, C5a, SC5b9

Measure: Complement activation

Time: At enrollment

Description: Measurement of factor B, factor H, factor I, C3a, C4a, C5a, SC5b9

Measure: Complement activation

Time: 28 days (+/-7) after enrollment

No related HPO nodes (Using clinical trials)